Form 4: Microbot Medical CEO Harel Gadot Reports Stock Option Grant and Vesting
SEC Form 4 Filing
Harel Gadot, CEO of Microbot Medical Inc., reports the acquisition of stock options and the vesting of performance-based options.
Summary
- On February 5, 2025, Harel Gadot, the Chairman, President, and CEO of Microbot Medical Inc., filed a Form 4.
- The filing reports the acquisition of 228,000 stock options with an exercise price of $2.04, vesting starting August 5, 2025, and continuing quarterly over 30 months.
- It also reports the vesting of 12,000 performance-based stock options, granted on February 26, 2024, with an exercise price of $1.25, after the Compensation Committee determined the milestones were met.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option activity. The vesting of performance-based options could be seen as slightly positive, but it's not a major event.
Positives
- The vesting of performance-based options suggests that certain company milestones have been achieved.
Future Outlook
NA
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Grant date of performance-based options |
| 02/05/2025 | Date of earliest transaction and vesting of performance-based options |
| 02/05/2025 | Date of Form 4 filing |
| 08/05/2025 | Initial vesting date for the newly acquired stock options |
| 02/26/2034 | Expiration date of performance-based options |
| 02/05/2035 | Expiration date of the newly acquired stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.